JP2012521366A - 膵臓β細胞機能不全の治療のための組織カリクレイン - Google Patents
膵臓β細胞機能不全の治療のための組織カリクレイン Download PDFInfo
- Publication number
- JP2012521366A JP2012521366A JP2012501089A JP2012501089A JP2012521366A JP 2012521366 A JP2012521366 A JP 2012521366A JP 2012501089 A JP2012501089 A JP 2012501089A JP 2012501089 A JP2012501089 A JP 2012501089A JP 2012521366 A JP2012521366 A JP 2012521366A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- purified
- klk1
- isolated
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 42
- 101710176219 Kallikrein-1 Proteins 0.000 title abstract description 17
- 102000057032 Tissue Kallikreins Human genes 0.000 title abstract description 17
- 230000004053 pancreatic β cell dysfunction Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 230000003820 β-cell dysfunction Effects 0.000 claims abstract description 11
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 39
- 150000001413 amino acids Chemical group 0.000 claims description 35
- 102100038297 Kallikrein-1 Human genes 0.000 claims description 31
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 20
- 108010003195 Kallidin Proteins 0.000 claims description 13
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 claims description 13
- 102000012479 Serine Proteases Human genes 0.000 claims description 13
- 108010022999 Serine Proteases Proteins 0.000 claims description 13
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 claims description 11
- 210000004153 islets of langerhan Anatomy 0.000 claims description 10
- 230000004064 dysfunction Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000010188 recombinant method Methods 0.000 claims description 3
- 238000011476 stem cell transplantation Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000006320 pegylation Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 53
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 44
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 40
- 229960001052 streptozocin Drugs 0.000 description 40
- 229940125396 insulin Drugs 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 102000004877 Insulin Human genes 0.000 description 25
- 108090001061 Insulin Proteins 0.000 description 25
- 201000010099 disease Diseases 0.000 description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical group 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000000496 pancreas Anatomy 0.000 description 11
- 101100453988 Homo sapiens KLK1 gene Proteins 0.000 description 10
- 102000001399 Kallikrein Human genes 0.000 description 10
- 108060005987 Kallikrein Proteins 0.000 description 10
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 210000000277 pancreatic duct Anatomy 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 229950004398 broxuridine Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000004923 pancreatic tissue Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108010077861 Kininogens Proteins 0.000 description 2
- 102000010631 Kininogens Human genes 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 101001050269 Mus musculus Kallikrein 1-related peptidase b1 Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700022175 Tissue Kallikreins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229940039088 kininogenase Drugs 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- -1 onokrein P Proteins 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 150000007649 L alpha amino acids Chemical class 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102400000966 Lysyl-bradykinin Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101000605521 Macaca fascicularis Kallikrein-1 Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 241000282515 Papio hamadryas Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000288960 Saguinus oedipus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 229960003709 kallidinogenase Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16317309P | 2009-03-25 | 2009-03-25 | |
| US61/163,173 | 2009-03-25 | ||
| PCT/CA2010/000413 WO2010108262A1 (en) | 2009-03-25 | 2010-03-25 | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521366A true JP2012521366A (ja) | 2012-09-13 |
| JP2012521366A5 JP2012521366A5 (enExample) | 2013-05-09 |
Family
ID=42780097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501089A Pending JP2012521366A (ja) | 2009-03-25 | 2010-03-25 | 膵臓β細胞機能不全の治療のための組織カリクレイン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120070425A1 (enExample) |
| EP (1) | EP2411042A4 (enExample) |
| JP (1) | JP2012521366A (enExample) |
| CN (1) | CN102438648A (enExample) |
| AU (1) | AU2010228068A1 (enExample) |
| CA (1) | CA2756801A1 (enExample) |
| NZ (1) | NZ595364A (enExample) |
| WO (1) | WO2010108262A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582930A (en) | 2007-07-20 | 2012-11-30 | Diamedica Inc | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| JP2014520119A (ja) * | 2011-06-17 | 2014-08-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | インスリン感受性を増大させる方法および糖尿病を処置するための方法 |
| WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| PT2854841T (pt) | 2012-06-04 | 2017-05-15 | Diamedica Inc | Isoformas de glicosilação da calicreína 1 em tecido humano |
| CN104073482A (zh) | 2013-12-30 | 2014-10-01 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化的组织激肽释放酶及其制备方法和应用 |
| US11857608B2 (en) | 2017-03-09 | 2024-01-02 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| CN112481268B (zh) * | 2021-01-25 | 2024-01-30 | 河南大学 | 一种棉花启动子PGhPGF及其重组载体和应用 |
| CN116135973A (zh) * | 2021-11-16 | 2023-05-19 | 江苏众红生物工程创药研究院有限公司 | 低糖基化修饰的激肽原酶及其聚乙二醇修饰物和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011713A1 (en) * | 2006-07-26 | 2008-01-31 | Diamedica Inc. | Methods of diagnosis and treatment for metabolic disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| JP2002516261A (ja) * | 1998-05-22 | 2002-06-04 | エンターメッド インコーポレイテッド | セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法 |
| CN1228447C (zh) * | 2001-02-20 | 2005-11-23 | 深圳市人民医院 | 一种含有人胰腺组织激肽释放酶成熟蛋白基因的重组表达载体 |
| CN100338212C (zh) * | 2003-01-29 | 2007-09-19 | 中国科学院大连化学物理研究所 | 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用 |
| JP2008515774A (ja) * | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| CN101094869A (zh) * | 2004-08-03 | 2007-12-26 | 戴埃克斯有限公司 | Hk1结合蛋白 |
| JP5322935B2 (ja) * | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| CN101134953B (zh) * | 2007-07-02 | 2011-02-09 | 广东天普生化医药股份有限公司 | 重组人胰激肽原酶 |
| CN101255438B (zh) * | 2008-04-11 | 2012-01-25 | 深圳大学 | 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法 |
-
2010
- 2010-03-25 EP EP10755352A patent/EP2411042A4/en not_active Ceased
- 2010-03-25 JP JP2012501089A patent/JP2012521366A/ja active Pending
- 2010-03-25 AU AU2010228068A patent/AU2010228068A1/en not_active Abandoned
- 2010-03-25 CN CN2010800181825A patent/CN102438648A/zh active Pending
- 2010-03-25 NZ NZ595364A patent/NZ595364A/xx not_active IP Right Cessation
- 2010-03-25 WO PCT/CA2010/000413 patent/WO2010108262A1/en not_active Ceased
- 2010-03-25 CA CA2756801A patent/CA2756801A1/en not_active Abandoned
-
2011
- 2011-09-23 US US13/241,882 patent/US20120070425A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008011713A1 (en) * | 2006-07-26 | 2008-01-31 | Diamedica Inc. | Methods of diagnosis and treatment for metabolic disorders |
Non-Patent Citations (2)
| Title |
|---|
| JPN6014015663; ＹＵＡＮ，Ｇ． ｅｔ ａｌ: 'Ｔｉｓｓｕｅ Ｋａｌｌｉｋｒｅｉｎ Ｒｅｖｅｒｓｅｓ Ｉｎｓｕｌｉｎ Ｒｅｓｉｓｔａｎｃｅ ａｎｄ Ａｔｔｅｎｕａｔｅｓ Ｎｅｐｈｒｏｐａｔｈｙ ｉｎ Ｄｉａｂｅｔｉｃ Ｒａｔｓ ｂｙ Ａｃｔｉｖａｔ' ＥＮＤＯＣＲＩＮＯＬＯＧＹ ｖｏｌ． １４８， ｎｏ． ５, 2007, ｐｐ．２０１６-２０２６ * |
| JPN6014015665; ＷＥＩＲ，Ｇ．Ｃ． ｅｔ ａｌ: 'Ｆｉｖｅ Ｓｔａｇｅｓ ｏｆ Ｅｖｏｌｖｉｎｇ Ｂｅｔａ-Ｃｅｌｌ Ｄｙｓｆｕｎｃｔｉｏｎ Ｄｕｒｉｎｇ Ｐｒｏｇｒｅｓｓｉｏｎ ｔｏ Ｄｉａｂｅｔｅｓ' ＤＩＡＢＥＴＥＳ ｖｏｌ． ５３ ｎｏ． ｓｕｐｐｌ ３, 2004, ｐｐ．Ｓ１６-Ｓ２１ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010108262A1 (en) | 2010-09-30 |
| AU2010228068A1 (en) | 2011-10-20 |
| US20120070425A1 (en) | 2012-03-22 |
| NZ595364A (en) | 2013-09-27 |
| EP2411042A1 (en) | 2012-02-01 |
| CN102438648A (zh) | 2012-05-02 |
| CA2756801A1 (en) | 2010-09-30 |
| EP2411042A4 (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhattamisra et al. | Type-3c diabetes mellitus, diabetes of exocrine pancreas-an update | |
| AU2019309796B2 (en) | Methods of using a GIP/GLP1 co-agonist for therapy | |
| Kruger et al. | Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data | |
| US20220152160A1 (en) | Dosing regimen | |
| CN102389413B (zh) | 用于治疗糖尿病的组合物及其应用 | |
| EP2411042A1 (en) | Tissue kallikrein for the treatment of pancreatic -cell dysfunction | |
| CN101914150B (zh) | 一种多肽及其在制药中的应用 | |
| US11938172B2 (en) | Method for regulating and controlling GLP-1/GLP-1R and drug | |
| Dungan et al. | Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) | |
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| JP2014534265A (ja) | インスリンアミノ酸配列を含む治療薬 | |
| JP2006506386A (ja) | 糖尿病の処置 | |
| Prasathkumar et al. | Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: an insight on molecular approaches | |
| CA2462543A1 (en) | Glucagon-like peptides (glp-1) and treatment of respiratory distress | |
| CN105753963B (zh) | 高活性艾塞那肽类似物及其医药应用 | |
| Boj-Carceller | Proton pump inhibitors: impact on glucose metabolism | |
| Chabenne et al. | Structural refinement of glucagon for therapeutic use | |
| US20010041669A1 (en) | Prevention of diabetes | |
| US20220315633A1 (en) | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake | |
| US8895505B2 (en) | Method of treatment of type 2 diabetes | |
| US20180030102A1 (en) | Application of metrnl protein in preparing hypolipidemic, hypoglycemic medicine | |
| Almohammad et al. | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry | |
| WO2000009147A1 (en) | Blood sugar level controlling agent | |
| US20020147134A1 (en) | Method of preventing and treating the complications of insulin dependent diabetes mellitus | |
| JPH0680584A (ja) | グリセンチンを有効成分とする医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130322 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130322 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150601 |